United Therapeutics Corporation (UTHR) Stock Analysis
Is UTHR a good investment?
United Therapeutics Corporation (UTHR) has a Plutrex AI rating of 73.0/100 as of August 22, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Fortress balance sheet and elite profitability: 86.1% gross margin, 42.2% operating margin, 41.6% net margin, zero debt, $2.66B cash, $557M FCF — top 1% of 173-company biotech peer group on every profitability and health metric, with no financial distress risk. Main concern: Revenue contraction of -1.9% is structural and ongoing — earnings growth of 13.4% is driven by buybacks and margin expansion, not organic revenue growth; five-year forward EPS growth decelerates to 7.6%, and a PEG of 2.36 on that growth rate means the stock requires pipeline optionality (ralinepag approval, Tyvaso IPF label expansion) to be realized to justify current pricing above the conservative DCF fair value range of ~$405-$475.
Investment Summary
United Therapeutics (UTHR) at $513.12 is a fortress-quality pharmaceutical company with exceptional profitability (86.1% gross margin, 42.2% operating margin, 41.6% net margin) and a pristine balance sheet ($2.66B cash, zero debt), but faces a structural growth challenge: revenue declined -1.9% while the biotech industry averaged +488% revenue growth. The stock trades at P/E of 18.47x with a PEG of 2.36 — overvalued on an absolute basis but at a 57.5% discount to the biotech industry average P/E of 43.42x. The analyst consensus target of $664.33 implies 29.5% upside. Recent news is incrementally positive: the ADVANCE OUTCOMES study for ralinepag published in The Lancet (showing 55% reduction in PAH clinical worsening events, hazard ratio 0.45) is a genuine pipeline catalyst, and completion of TETON-PPF Phase III enrollment keeps Tyvaso's label expansion on track. The stock has risen 2.7% from $499.73 to $513.12 since the prior report, moving slightly above the upper end of the prior entry zone ($490-$515). The investment thesis remains intact — exceptional quality business with pipeline optionality — but the modest price appreciation has slightly reduced the risk/reward versus one week ago.
Key Strengths
- Fortress balance sheet and elite profitability: 86.1% gross margin, 42.2% operating margin, 41.6% net margin, zero debt, $2.66B cash, $557M FCF — top 1% of 173-company biotech peer group on every profitability and health metric, with no financial distress risk
- Ralinepag pipeline catalyst with ADVANCE OUTCOMES results published in The Lancet showing 55% reduction in PAH clinical worsening events (hazard ratio 0.45), plus TETON-PPF Phase III fully enrolled — two genuine revenue re-acceleration opportunities that could resolve the structural revenue contraction concern
- Sector-relative valuation discount: P/E of 18.47x is 57.5% below the biotech industry average of 43.42x, and PEG of 2.36 is 61.9% below the industry average of 6.19x — UTHR is one of the cheapest profitable biotechs in the sector, with analyst consensus implying 29.5% upside to $664.33
Key Concerns
- Revenue contraction of -1.9% is structural and ongoing — earnings growth of 13.4% is driven by buybacks and margin expansion, not organic revenue growth; five-year forward EPS growth decelerates to 7.6%, and a PEG of 2.36 on that growth rate means the stock requires pipeline optionality (ralinepag approval, Tyvaso IPF label expansion) to be realized to justify current pricing above the conservative DCF fair value range of ~$405-$475
- Stock has risen 2.7% from $499.73 to $513.12, moving to the upper end of the prior entry zone ($490-$515) — the risk/reward has modestly deteriorated; at $513.12, the upside to analyst consensus ($664.33) is 29.5% while downside to stop-loss ($455) is -11.3%, yielding a risk/reward ratio of approximately 2.6:1, still acceptable but less compelling than the 3.37:1 ratio available one week ago
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
UTHR's fundamentals are bifurcated: elite profitability/health vs. weak growth. Profitability: Gross margin 86.1% (vs. industry 32.9%), operating margin 42.2% (vs. industry -6,068%), net margin 41.6% (vs. industry -3,388%), ROE 19.3% (vs. industry -72.6%) — UTHR is in the top 1% of its 173-company biotech peer group on every profitability metric. Financial Health: Zero debt (D/E: N/A vs. industry 1.07), $2.66B cash, $557M annual free cash flow — fortress balance sheet with no financial distress risk. Valuation: P/E 18.47x (vs. industry 43.42x, a 57.5% discount), PEG 2.36 (vs. industry 6.19, a 61.9% discount) — cheap relative to peers but PEG of 2.36 signals absolute overvaluation given only 7.6% five-year EPS growth. Growth: Revenue -1.9% (vs. industry +488%), forward EPS growth 10.5% next year and 7.6% five-year CAGR (vs. industry 173.9% and 18.5% respectively) — UTHR is a mature compounder, not a growth engine. The negative revenue growth while earnings grow 13.4% confirms earnings expansion is driven by buybacks and margin expansion, not organic business growth. Fair value on a standalone PEG basis (1.0-1.5x applied to 7.6% growth) implies P/E of 7.6-11.4x, or intrinsic value of ~$300-$450 — but pipeline optionality (ralinepag, Tyvaso IPF) justifies a premium above this range.
News Sentiment
United Therapeutics is quietly building a compelling comeback story — and Wall Street is starting to pay attention. The specialty pharmaceutical company, best known for its pulmonary arterial hypertension (PAH) treatments, delivered Q2 2026 earnings that beat analyst estimates, with year-over-year earnings growth of 13.4% compared to $6.41 EPS in Q2 2025. But the real excitement is in the pipeline. The headline 'ADVANCE OUTCOMES study results for ralinepag published in The Lancet' is the most significant development for long-term investors. The Lancet is the gold standard of medical journals, and publication there signals that ralinepag's 55% reduction in PAH clinical worsening events is scientifically credible and ready for regulatory scrutiny — a major step toward potential FDA approval that could reignite the company's revenue growth engine. Meanwhile, 'UTHR Completes Phase III Tyvaso Study Enrollment for Expanded Label' means the company's flagship drug Tyvaso is on track to potentially treat pulmonary fibrosis patients beyond its current PAH indication — a market expansion that analysts believe could be worth hundreds of millions in additional annual revenue. The appointment of Victor Dzau, M.D., to the Board of Directors adds scientific credibility to the company's governance. The Q2 earnings call highlighted that while core revenues face modest pressure, the pipeline is advancing on multiple fronts. For everyday investors, the story is simple: this is a highly profitable, debt-free company with $2.66 billion in cash, betting on two major pipeline catalysts to reignite growth.
Risk Assessment
PRIMARY RISK: Pipeline failure — if ralinepag Phase 3 does not achieve regulatory approval or Tyvaso IPF label expansion is rejected, the revenue contraction narrative has no resolution catalyst and the stock could re-rate toward the standalone DCF fair value of $405-$475, implying 7-21% downside from current levels. SECONDARY RISK: Continued revenue erosion — if Q3/Q4 2026 results show accelerating revenue decline beyond -1.9%, the earnings growth story (currently sustained by buybacks and margin expansion) becomes increasingly fragile. TERTIARY RISK: Valuation compression — at P/E 18.47x with only 7.6% five-year EPS growth, any multiple compression toward the growth-justified P/E of 10-12x would be painful. MITIGATION: Stop-loss at $455 (11.3% below current price) limits downside; the $2.66B cash fortress and zero debt provide a fundamental floor; pipeline catalysts (ralinepag, TETON-PPF readout) provide asymmetric upside optionality. Position sizing at 3.5% of portfolio limits concentration risk in a single pipeline-dependent thesis.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is UTHR a halal stock?
No, United Therapeutics Corporation (UTHR) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for UTHR?
United Therapeutics Corporation (UTHR) has a Plutrex AI rating of 73.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is UTHR a good investment?
According to Plutrex AI, UTHR has a Buy rating (73.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in UTHR?
US stocks like UTHR can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in UTHR?
Plutrex AI identifies the main risks for UTHR by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.